Trial Profile
TPExtreme: Randomized, Controlled Trial of Platinum-Cetuximab Combined Either With Docetaxel (TPEx) or With 5FU (Extreme) in Patients With Recurrent/Metastatic Squamous Cell Cancer of the Head and Neck
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Aug 2023
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Carboplatin; Cisplatin; Docetaxel; Fluorouracil; Granulocyte colony-stimulating factors
- Indications Carcinoma; Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms TPExtreme
- 22 Aug 2022 Status changed from active, no longer recruiting to completed.
- 10 Mar 2022 Planned End Date changed from 1 Sep 2021 to 1 Dec 2022.
- 10 Mar 2022 Planned primary completion date changed from 1 Jan 2021 to 1 Dec 2022.